PT1849470T - Fármaco anticancro contendo alfa, alfa, alfa-trifluorotimidina e inibidor da timidina-fosforilase - Google Patents

Fármaco anticancro contendo alfa, alfa, alfa-trifluorotimidina e inibidor da timidina-fosforilase

Info

Publication number
PT1849470T
PT1849470T PT67122929T PT06712292T PT1849470T PT 1849470 T PT1849470 T PT 1849470T PT 67122929 T PT67122929 T PT 67122929T PT 06712292 T PT06712292 T PT 06712292T PT 1849470 T PT1849470 T PT 1849470T
Authority
PT
Portugal
Prior art keywords
alpha
trifluorotimidin
timidine
anticancer drug
drug containing
Prior art date
Application number
PT67122929T
Other languages
English (en)
Portuguese (pt)
Inventor
Emura Tomohiro
Mita Akira
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36740357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1849470(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/042,059 external-priority patent/US7799783B2/en
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of PT1849470T publication Critical patent/PT1849470T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT67122929T 2005-01-26 2006-01-25 Fármaco anticancro contendo alfa, alfa, alfa-trifluorotimidina e inibidor da timidina-fosforilase PT1849470T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/042,059 US7799783B2 (en) 2005-01-26 2005-01-26 Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
JP2005165156 2005-06-06

Publications (1)

Publication Number Publication Date
PT1849470T true PT1849470T (pt) 2017-09-22

Family

ID=36740357

Family Applications (1)

Application Number Title Priority Date Filing Date
PT67122929T PT1849470T (pt) 2005-01-26 2006-01-25 Fármaco anticancro contendo alfa, alfa, alfa-trifluorotimidina e inibidor da timidina-fosforilase

Country Status (20)

Country Link
EP (1) EP1849470B2 (enExample)
JP (1) JP5576591B2 (enExample)
KR (1) KR101468216B1 (enExample)
AU (1) AU2006209547C1 (enExample)
BE (1) BE2017C028I2 (enExample)
CA (1) CA2594713A1 (enExample)
CY (2) CY2017029I2 (enExample)
DK (1) DK1849470T4 (enExample)
ES (1) ES2630002T5 (enExample)
FI (1) FI1849470T4 (enExample)
FR (1) FR17C1028I2 (enExample)
HU (2) HUE033306T2 (enExample)
LT (2) LT1849470T (enExample)
LU (1) LUC00036I2 (enExample)
NL (1) NL300889I2 (enExample)
PL (1) PL1849470T5 (enExample)
PT (1) PT1849470T (enExample)
SI (1) SI1849470T2 (enExample)
TW (1) TWI362265B (enExample)
WO (1) WO2006080327A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DK1849470T4 (en) 2005-01-26 2024-04-02 Taiho Pharmaceutical Co Ltd Cancerlægemiddel, som indeholder alpha, alpha, alpha-trifluorthymidin og thymidin-phosphorylase-inhibitor
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
PL2148676T3 (pl) * 2007-04-25 2016-12-30 Stosowanie sapacytabiny do leczenia choroby proliferacyjnej
TWI454288B (zh) 2008-01-25 2014-10-01 Gruenenthal Chemie 藥物劑型
ES2599031T3 (es) 2008-05-09 2017-01-31 Grünenthal GmbH Proceso para la preparación de una formulación de polvo intermedia y una forma de dosificación solida final utilizando un paso de congelación por pulverización
CA2723944A1 (en) * 2008-05-15 2009-11-19 Jan Balzarini Anti-cancer combination therapy
BR112012001466A2 (pt) 2009-07-22 2020-08-11 Grünenthal GmbH forma de dosagem resistente à falsificação para opioides sensíveis à oxidação, seu processo de fabricação, e embalagem
ES2534908T3 (es) 2009-07-22 2015-04-30 Grünenthal GmbH Forma de dosificación de liberación controlada extruida por fusión en caliente
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
BR112014002022A2 (pt) 2011-07-29 2017-02-21 Gruenenthal Gmbh comprimido resistente à violação proporcionando liberação de fármaco imediata
JP6063462B2 (ja) 2011-07-29 2017-01-18 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時薬剤放出を提供するタンパーレジスタント錠剤
PL2746404T3 (pl) 2011-08-16 2018-04-30 Taiho Pharmaceutical Co., Ltd. Środek przeciwnowotworowy i sposób przewidywania efektu terapeutycznego u pacjentów z rakiem jelita grubego z mutacją kras
TWI503122B (zh) * 2012-02-15 2015-10-11 Taiho Pharmaceutical Co Ltd Oral administration of pharmaceutical compositions
TWI526210B (zh) * 2012-02-15 2016-03-21 Taiho Pharmaceutical Co Ltd Oral pharmaceutical composition
BR112014019988A8 (pt) 2012-02-28 2017-07-11 Gruenenthal Gmbh Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico
LT2838512T (lt) 2012-04-18 2018-11-12 GrĆ¼nenthal GmbH Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CN104349779A (zh) * 2012-05-16 2015-02-11 诺华股份有限公司 Pi-3激酶抑制剂的剂量方案
US9616081B2 (en) * 2013-03-27 2017-04-11 Taiho Pharmaceutical Co., Ltd. Antitumor agent including low-dose irinotecan hydrochloride hydrate
UA114840C2 (uk) * 2013-03-27 2017-08-10 Тайхо Фармасьютікал Ко., Лтд. Протипухлинний агент, який включає гідрат гідрохлориду іринотекану
JP6312660B2 (ja) * 2013-05-17 2018-04-18 大鵬薬品工業株式会社 Ｔｋ１タンパク質の発現が亢進した結腸直腸癌患者に対する治療効果予測方法
MX2015016254A (es) 2013-05-29 2016-04-20 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
AU2014316030C1 (en) 2013-09-06 2024-08-15 Les Laboratoires Servier Antitumor agent and antitumor effect enhancer
HK1224189A1 (zh) 2013-11-26 2017-08-18 Grünenthal GmbH 通过低温研磨制备粉状药物组合物
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
EP3693019A1 (en) 2016-01-08 2020-08-12 Taiho Pharmaceutical Co., Ltd. Anti-tumor agent containing immunomodulator
KR102412690B1 (ko) 2016-02-05 2022-06-23 다이호야쿠힌고교 가부시키가이샤 중증 신장 기능 장애를 갖는 암 환자에 대한 치료 방법
EP3730935A4 (en) 2017-12-22 2022-02-23 Taiho Pharmaceutical Co., Ltd. METHOD OF DETECTING ANALOGUES OF TRIFLURIDIN AND/OR TIPIRACIL
US10866219B2 (en) 2017-12-22 2020-12-15 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine- and/or tipiracil-related substance
US10816517B2 (en) 2018-01-05 2020-10-27 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine-related substance by high-performance liquid chromatography
WO2019135405A1 (ja) 2018-01-05 2019-07-11 大鵬薬品工業株式会社 トリフルリジン由来の類縁物質の検出方法
US20260021045A1 (en) * 2024-07-17 2026-01-22 Jnd Therapeutics, Inc. Methods and formulations for treatment of liver cancer using trifluridine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3088757B2 (ja) 1995-03-29 2000-09-18 大鵬薬品工業株式会社 ウラシル誘導体並びにそれを含有する抗腫瘍効果増強剤及び抗腫瘍剤
EP0884051B1 (en) * 1996-09-24 2004-12-15 Taiho Pharmaceutical Company Limited Cancerous metastasis inhibitors containing uracil derivatives
DK1849470T4 (en) 2005-01-26 2024-04-02 Taiho Pharmaceutical Co Ltd Cancerlægemiddel, som indeholder alpha, alpha, alpha-trifluorthymidin og thymidin-phosphorylase-inhibitor

Also Published As

Publication number Publication date
RU2007132181A (ru) 2009-03-10
JPWO2006080327A1 (ja) 2008-06-19
LUC00036I2 (enExample) 2017-12-01
FR17C1028I2 (fr) 2018-11-02
LUC00036I1 (enExample) 2017-10-02
PL1849470T3 (pl) 2017-11-30
ES2630002T5 (es) 2024-09-19
DK1849470T4 (en) 2024-04-02
BE2017C028I2 (enExample) 2025-09-10
CY2017029I1 (el) 2018-02-14
JP5576591B2 (ja) 2014-08-20
EP1849470A4 (en) 2010-12-08
LTC1849470I2 (lt) 2019-10-25
ES2630002T3 (es) 2017-08-17
AU2006209547A1 (en) 2006-08-03
TW200637562A (en) 2006-11-01
CY2017029I2 (el) 2018-02-14
SI1849470T2 (sl) 2024-05-31
TWI362265B (en) 2012-04-21
SI1849470T1 (sl) 2017-10-30
PL1849470T5 (pl) 2024-06-10
NL300889I2 (nl) 2018-01-16
AU2006209547B2 (en) 2011-05-26
FI1849470T4 (fi) 2024-03-22
AU2006209547C1 (en) 2022-04-07
EP1849470A1 (en) 2007-10-31
EP1849470B2 (en) 2024-03-20
HUS1700032I1 (hu) 2017-09-28
NL300889I1 (nl) 2017-08-14
CA2594713A1 (en) 2006-08-03
LTPA2017024I1 (lt) 2017-08-10
CY1119393T1 (el) 2018-02-14
EP1849470B1 (en) 2017-06-21
WO2006080327A1 (ja) 2006-08-03
KR101468216B1 (ko) 2014-12-03
LT1849470T (lt) 2017-07-25
FR17C1028I1 (enExample) 2017-09-29
HUE033306T2 (hu) 2017-11-28
KR20070104559A (ko) 2007-10-26
DK1849470T3 (en) 2017-08-14
RU2394581C2 (ru) 2010-07-20

Similar Documents

Publication Publication Date Title
CY2017029I2 (el) ΑΝΤΙΚΑΡΚΙΝΙΚΟ ΦΑΡΜΑΚΟ ΠΟΥ ΠΕΡΙΕΧΕΙ α,α,α-ΤΡΙΦΘΟΡΟΘΥΜΙΔΙΝΗ ΚΑΙ ΑΝΑΣΤΟΛΕΑ ΦΩΣΦΟΡΥΛΑΣΗΣ ΘΥΜΙΔΙΝΗΣ
DK1907037T3 (da) Medikamentdispenser.
HUS1400051I1 (hu) Lurazidont tartalmazó gyógyászati készítmény
BRPI0815773A2 (pt) composto, e, medicamento.
EP1992348A4 (en) PHARMACEUTICAL COMBINATION
EP1967126A4 (en) CONTAINER DEVICE
NL2000480A1 (nl) Nieuwe farmaceutische middelen.
DK2254873T3 (da) Benzodiazepinforbindelse og farmaceutisk sammensætning.
DK1957073T3 (da) Lægemiddel
DK2029561T3 (da) Tricyclisk forbindelse og farmaceutisk anvendelse deraf
DE602006020744D1 (de) Fertigspritze
NL1032915A1 (nl) Katheterpunt.
DK1757293T3 (da) Bh4-responsiv hyperphenylalaninæmi-medikamenter
EP1937255A4 (en) PHARMACEUTICAL COMPOSITION
EP1917967A4 (en) DRUG AGAINST AIDS
EP1862184A4 (en) PHARMACEUTICAL COMPOSITION
BRPI0614413A2 (pt) composto, e, composição farmacêutica
EP1941909A4 (en) PREVENTIVE MEASURES / REMEDIES FOR CANCER
BRPI0614412A2 (pt) composto, e, composição farmacêutica
ITMI20040943A1 (it) Composizione farmaceutica cicatrizzante
DE112006001760A5 (de) Katheter
UA11573S (uk) Етикетка лікарського засобу
BRPI0719398A2 (pt) Composição farmacêutica.
EP1889632A4 (en) MEANS FOR THE TREATMENT OF XANTHOM
UA10369S (uk) Таблетка фармацевтична